Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...

WICHITA, Kan. (KWCH) - Kansas children battling leukemia have a new hope for survival thanks to a new treatment available in Wichita. KU School of Medicine-Wichita Doctors Nathan Hall and Brian Pate ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

After a brief period of being cancer-free, Stewart's leukemia relapses, leading to the need for a bone marrow transplant. The hope is that Jimmy will be the perfect match, but fate has other plans.

Single-cell technologies uncover how leukemia cells evolve, resist therapy, and survive through cell-to-cell communication.

Leukemia is a blood cancer with abnormal white blood cell overproduction, affecting red blood cells and platelets, leading to anemia and infection risks. Diagnosis involves blood tests, bone marrow ...

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage. If approved, the ...

After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.